RISK SCORE CALCULATOR.xlsx - http;//links.lww.com

(1)

Supplementary table 1. NADC and ADC distribution.

Abbreviations: NADC non-AIDS defining cancer, ADC AIDS-defining cancer,ICD international classification of diseases.

Cancer site (ICD-10) No

AIDS-defining cancers

Kaposi’s sarcoma (C46) 184

Cervix Uteri (C53) 34

Non-AIDS-defining cancers

Lip, oral cavity and pharynx (C00-C14) 12

Esophagus and stomach (C15-16) 14

Small intestine and colon (C17-18) 7

Rectum-anus (C19-21) 31

Liver, primary (C22) 69

Gallbladder, biliary tract and pancreas (C23-25) 6

Larynx (C32) 7

Lung, bronchus and trachea (C33-34) 35 Heart, mediastinum and pleura (C38) 1 Bone and articular cartilage (C40-41) 2

Melanoma (C43) 16

Skin non-melanoma (C44) 46

Connective and soft tissue (C45-49) 4

Breast (C50) 30

Vagina and vulva (C51-52, 57) 5

Uterus and ovary (C55-56) 5

Penis (C60) 8

Prostate (C61) 8

Testis (C62) 13

Kidney (C64-66, C68) 9

Bladder (C67) 7

Eye (C69) 1

Brain and CNS (C70-72) 5

Endocrine glands and related structures (C73-75) 8

Malignant neoplasm of other and ill-defined sites (C76) 6

(2)

Supplementary table 2. Areas under the ROC curve using various prognostic variables.

Abbreviations:ROC receiver operating characteristics, NADC non-AIDS defining cancer, ADC AIDS-defining cancer, 95% CI 95% confidence interval, GPS Glasgow Prognostic Score, mGPS modified Glasgow Prognostic Score, NLR neutrophil/lymphocyte ratio, PLR platelet/lymphocyte ratio, PI Prognostic Index, PNI Prognostic Nutritional Index.The bold numbers are those concerning variables resulted significantly predictive of death.

Solid NADCs Solid ADCs

Prognostic

variable Area under the

ROC curve (95% CI)

Area under the ROC curve (95% CI)

GPS

0.65 (0.55-0.76) 0.66 (0.47-0.85)

mGPS

0.65 (0.54-0.76) 0.46 (0.21-0.72)

NLR

0.56 (0.51-0.60) 0.53 (0.46-0.61)

PLR

0.53 (0.48-0.58) 0.56 (0.47-0.65)

PI

0.59 (0.50-0.67) 0.54 (0.38-0.71)

PNI

0.65 (0.59-0.71) 0.61 (0.49-0.73)

(3)

Supplementary table 3. Cox regression analyses for mortality in the derivation subgroup: variables associated with survival of patients with solid non‐AIDS‐defining cancer.

Abbreviations: NADC non-AIDS-defining cancer, HR hazard ratio, 95% CI 95% confidence interval, IDU intravenous drug use, HBV hepatitis B virus

,

^HCV

hepatitis C virus, ART antiretroviral therapy, PNI Prognostic Nutritional Index. *Adjusted for all the variables in the table.

πThe mortality risk score based on the regression coefficients of the variables in final model for NADCs was represented by 0.035*(age at diagnosis) + 0.496*(IDU [yes =1/no=0]) +1.046*(PNI).

Solid NADCs

Variable Category

Univariate analysis Multivariate analysis^π HR

(

CI 95%)*

P value HR

(

CI 95%)*

P value Gender Male vs Female 1.90(0.44-2.36) NS

Age (years) 1.02 (1.01-1.04) 0.023 1.03 (1.01-1.06) 0.018

IDU Yes vs No 1.45 (0.98-2.14) 0.060 1.64 (0.92-2.95) 0.096

Previous AIDS defining event

Yes vs No 1.24 (0.84-1.82) NS

HBV or/and HCV co- infection

Yes vs No 1.14 (0.77-1.70) NS

ART Yes vs No 0.82 (0.47-1.41) NS

CD4 cell count, cell/mm3

<200 vs ≥200 1.09 (0.70-1.68) NS

HIV-RNA

undetectable Yes vs No 1.16 (0.77-1.75) NS

PNI 3.11 (1.85-5.22) <0.001 2.85 (1.67-4.84) <0.001

(4)

MORTALITY RISK SCORE

For HIV infected patients with diagnosis of solid non‐AIDS defining cancer Reference

Endpoint All‐cause mortality

Do not leave blank:

Age (in years)

Intravenous drug use (0 for no; 1 for yes) Lymphocyte count (/μl)

Albumin (g/dl)

PNI 1

1 years 3 years 5 years

Risk score 1.05 Comulative risk of death (in %) 5.18 9.62 12.52

Disclaimer: Authors do not hold responsible for clinical consequences when people use this digital calculator as this is for reference only.

Baseline hazards were 0.9815, 0.9651 and 0.9541 at 1, 3 and 5 year from cancer dignosis, respectively (under the condition that risk score=0).